Authors
Latest:
Financial Toxicity: Tracking a Growing Side EffectJeremy Schafer and Deborah Lotterman discuss the impact that financial toxicity is having on patients and payers and outline the strategies pharma need to adopt to begin to remedy it.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Key Regulatory Deadlines Loom for Drug Dispensers and WholesalersThe COVID-19 pandemic is currently top of mind among pharma professionals, but stakeholders have other business to attend to – such as the upcoming deadline to meet regulatory requirements of the US FDA’s 2013 Drug Supply Chain Security Act.
Latest:
AI & Lab Data: Enabling Decision-Making in Real TimeLisa Kerber outlines how the pharma industry can take advantage of combining new clinical data sources such as diagnostics, or lab data, with AI to deliver on the promise of improving outcomes.
Latest:
Can A New Value Framework Help Ease Friction Over Orphan Drug Prices?Even on the contentious topic of orphan drug pricing, the last few months have brought hopeful signs that patients, pharmaceutical companies, health insurers, and the academic bodies that counsel them are trying to speak the same language.
Latest:
mHealth: Changing the Dynamics of the Healthcare EcosystemmHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.
Latest:
Why Your Advertising Agency Should Be Your Analytics PartnerBrands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.
Latest:
Navigating the Untapped NASH MarketA potential rush of treatment options on the horizon for non-alcoholic steatohepatitis will require skillful maneuvering in this likely lucrative but uncharted therapeutic market.
Latest:
The Rising Tide of Next Generation Cancer TreatmentsThe Ipsos Healthcare Oncology Centre of Excellence's Jackie Ilacqua & Valerie Wriede trace the evolution of cancer treatment and drill down into the latest developments currently redefining the landscape, together with those on the horizon.
Latest:
NASH: Pointers for Pharma from the Patient PerspectiveWith the NASH pipeline filling up fast, Mariel Metcalfe looks at what pharma companies need to do to ensure their products do not end up as also-rans in this dynamic new market segment.
Latest:
How Pharmas, Payers, and Providers Can Meet the ‘Triple Aim’Today’s model requires a fourth partner-the systems integrator
Latest:
Rebooting Life Sciences with DigitalMastering digital business strategies and tactics will enable life sciences companies to supercharge innovation and speed therapy discovery, patient centric-practices and improved health outcomes, writes Bhaskar Sambasivan.
Latest:
e-Data and the Biopharmaceutical Supply ChainMilliporeSigma’s Stephen Wing, head of Analytical and Logistical Services, discusses the ways in which digital transformation and data transparency dramatically enhance supply chains, and how manufacturers are using the company’s eMERGE™ platform to improve overall efficiencies.
Latest:
Are We Slaves to Predictability?The status quo pharma marketing model is still relied upon by the big brands, not because the results are amazing, but because they are predictable. It's time to challenge convention, says James Talerico.
Latest:
When HIPAA Doesn’t ApplyOutlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.
Latest:
When HIPAA Doesn’t ApplyOutlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.
Latest:
How Can We Be Healthcare Leaders Right Now?Brenda Gleason discusses the current health policy landscape and how future pharmacists can be healthcare leaders during a lecture at University of North Carolina Eshelman School of Pharmacy.
Latest:
Resilience in a Sea of Change: Ed Gudaitis, GM – Canada, AllerganEd Gudaitis Allergan VP and Country Manager, Canada, explains how embracing disruption is his secret to success.
Latest:
Developing Drugs for Rare Diseases: Insights for Pharma ExecsThis article explores the difficult nature of developing drugs for rare diseases and discusses what a pharmaceutical executive can actively do to help increase success.
